ATE422362T1 - Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose - Google Patents

Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose

Info

Publication number
ATE422362T1
ATE422362T1 AT02788511T AT02788511T ATE422362T1 AT E422362 T1 ATE422362 T1 AT E422362T1 AT 02788511 T AT02788511 T AT 02788511T AT 02788511 T AT02788511 T AT 02788511T AT E422362 T1 ATE422362 T1 AT E422362T1
Authority
AT
Austria
Prior art keywords
cop
lateral sclerosis
amyotrophic lateral
vaccines
treating amyotrophic
Prior art date
Application number
AT02788511T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE422362T1 publication Critical patent/ATE422362T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT02788511T 2001-12-06 2002-12-05 Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose ATE422362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
ATE422362T1 true ATE422362T1 (de) 2009-02-15

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788511T ATE422362T1 (de) 2001-12-06 2002-12-05 Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose

Country Status (23)

Country Link
US (1) US7351686B2 (de)
EP (1) EP1429800B1 (de)
JP (1) JP4542339B2 (de)
KR (1) KR20040081431A (de)
CN (2) CN1617736A (de)
AT (1) ATE422362T1 (de)
AU (1) AU2002353486B2 (de)
CA (1) CA2469092C (de)
CY (1) CY1109044T1 (de)
DE (1) DE60231131D1 (de)
DK (1) DK1429800T3 (de)
ES (1) ES2322566T3 (de)
HU (1) HU228207B1 (de)
IL (1) IL160105A0 (de)
IS (1) IS2670B (de)
MX (1) MXPA04005537A (de)
NO (1) NO336231B1 (de)
NZ (1) NZ533356A (de)
PL (1) PL205469B1 (de)
PT (1) PT1429800E (de)
RU (1) RU2303996C2 (de)
SI (1) SI1429800T1 (de)
WO (1) WO2003047500A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
EP1684797A1 (de) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vakzine und verfahren zur behandlung von neurodegenerativen erkrankungen
CA2548310C (en) 2003-12-09 2014-02-18 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
CA2558380A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
RU2410115C2 (ru) * 2004-05-07 2011-01-27 Пептиммьюн, Инк. Способы лечения заболеваний с помощью статистических сополимеров
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2615506A1 (en) * 2005-07-15 2007-01-25 Novartis Ag Pamps, pathogen associated molecular patterns
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013084236A1 (en) * 2011-12-05 2013-06-13 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als)
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
US20150238582A1 (en) 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) * 1996-09-27 2003-09-10 Гилфорд Фармасьютикалз Инк. Способ лечения глутаматных расстройств
AU2868699A (en) * 1998-02-13 1999-08-30 Autoimmune, Inc. Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1039929A1 (de) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Aktivierten t-zellen und deren verwendung
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
EP1248643B1 (de) * 2000-01-20 2005-08-17 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
DE60116467T2 (de) * 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
SI1429800T1 (sl) 2009-08-31
PL205469B1 (pl) 2010-04-30
CN1617736A (zh) 2005-05-18
WO2003047500A2 (en) 2003-06-12
WO2003047500A3 (en) 2004-03-18
NZ533356A (en) 2006-10-27
DE60231131D1 (de) 2009-03-26
EP1429800A2 (de) 2004-06-23
RU2004120536A (ru) 2005-03-27
EP1429800A4 (de) 2006-03-22
DK1429800T3 (da) 2009-04-27
JP2005515198A (ja) 2005-05-26
NO336231B1 (no) 2015-06-22
PT1429800E (pt) 2009-04-27
ES2322566T3 (es) 2009-06-23
MXPA04005537A (es) 2004-11-01
RU2303996C2 (ru) 2007-08-10
CA2469092C (en) 2013-02-19
PL370070A1 (en) 2005-05-16
CA2469092A1 (en) 2003-06-12
HUP0500039A2 (hu) 2005-03-29
HUP0500039A3 (en) 2010-01-28
EP1429800B1 (de) 2009-02-11
NO20042833L (no) 2004-08-12
CN102151330B (zh) 2017-04-12
HK1067043A1 (en) 2005-04-01
CY1109044T1 (el) 2014-07-02
IS7296A (is) 2004-06-03
AU2002353486B2 (en) 2009-01-15
AU2002353486A1 (en) 2003-06-17
KR20040081431A (ko) 2004-09-21
US7351686B2 (en) 2008-04-01
CN102151330A (zh) 2011-08-17
US20050220802A1 (en) 2005-10-06
JP4542339B2 (ja) 2010-09-15
IL160105A0 (en) 2004-06-20
HU228207B1 (hu) 2013-01-28
IS2670B (is) 2010-09-15

Similar Documents

Publication Publication Date Title
DE60231131D1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
SE9302308L (sv) Proteinberedning
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
DE60032250D1 (de) Behandlung von Allergien
BR0111195A (pt) Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
DE69730476D1 (de) Albumin als aktiven bestandteil zur behandlung von bindehaut- und hornhautverletzungen und von trockenen augen
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
DE69628844D1 (de) Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
EP1958960A3 (de) Verfahren für die Herstellung einer nicht-toxischen Anthrax-Impfung
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
PT1015595E (pt) Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
NO20034453L (no) Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
DE60212349D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines pharmazeutischen mittels zur prävention und behandlung von sexuellen störungen
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
ATE415419T1 (de) Inaktivierte zytokine zur immunisierung
ATE296640T1 (de) Methode und mittel zur behandlung eines post- poliosyndroms
EP1113073A3 (de) Leishmania Anitgene für Verwendung in Therapie und Diagnose von Leishmaniasis
ATE349532T1 (de) Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1429800

Country of ref document: EP